A Phase 2 Study of TRS005 in Patients With CD20-positive R/R DLBCL.
NCT06886139
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
139
Enrollment
INDUSTRY
Sponsor class
Conditions
CD20-positive Diffuse Large B-Cell Lymphoma
Interventions
DRUG:
TRS005
Sponsor
Zhejiang Teruisi Pharmaceutical Inc.